Sign in
Taking people in South KoreaPhase 4

Testing an added blood-thinning drug after a stroke from narrowed large arteries

Tests cilostazol added to standard blood thinners in adults with stroke from artery narrowing.

Key facts

Who runs it
Asan Medical Center
Where
Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul, and Yangsan, South KoreaSee the 24 sites
Trial code
Registry title
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Status
Recruiting
Phase
Phase 4
People taking part
2,340 people, planned
Started
10 Jul 2025
Expected to end
31 Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Aspirin
  • Clopidogrel
  • Cilostazol
  • Placebo
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have just had a stroke caused by hardening and narrowing of a large artery, and who can give consent within 72 hours of the stroke starting.

Age
20 years or older
Sex
Women and men can join.
Disease stage
Acute stroke from large artery atherosclerosis (inside or outside the skull). A scan shows a brain lesion and a narrowed artery next to it, with more than 50% diameter reduction, confirmed by MR angiography or CT angiography.

Main reasons for not taking part

  • Large stroke that prevents starting antiplatelet treatment
  • Bleeding in the brain, or early bleeding in the stroke area
  • Previous mRS higher than 2
  • Needs blood-thinning (anticoagulant) treatment
  • Cannot take aspirin, clopidogrel or cilostazol

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age of 20 years or older
  • Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography
  • Informed consent obtained within 72h from stroke onset
  • Acquisition of written informed consent prior to study entry

Who cannot take part

  • Previous mRS higher than 2
  • Pre-planned for surgery
  • Combined with acute intracranial haemorrhage
  • Large infarction unable to start antiplatelet treatment
  • With initial haemorrhagic transformation
  • Indicated for anticoagulation
  • Contraindication for aspirin, clopidogrel or cilostazol
  • Requirement of long term NSAID
  • Unable to withdraw consent
  • Unavailable to participate based on judgement of the investigator
  • Participants of reproductive potential (PORP)/ Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception

Where in South Korea

  • Pusan National University HospitalBusan, South KoreaContact: Hanjun ChoTaking people
  • Chungbuk National University HospitalCheongju-si, South KoreaContact: Hee-yoon Chae, MD, PhDTaking people
  • Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Mi-Yeon Eun, MD, PhDTaking people
  • Chungnam National University HospitalDaejeon, South KoreaContact: Jong Wook Shin, MD, PhDTaking people
  • Eulji University HospitalDaejeon, South KoreaContact: Jae Guk Kim, MD, PhDTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Kang-Ho Choi, MD, PhDTaking people
  • Hallym University Medical CenterGyeonggi-do, South KoreaContact: Minwoo Lee, MD, PhDTaking people
  • Hanyang University Guri HospitalGyeonggi-do, South KoreaContact: Hyuk Sung Kwon, MD, PhDTaking people
  • Korea University Ansan HospitalGyeonggi-do, South KoreaContact: Jin-Man Jung, MD, PhDTaking people
  • Seoul National University Bundang HospitalGyeonggi-do, South KoreaContact: Beom Joon Kim, MD, PhDTaking people
  • Gachon University Gil Medical CenterIncheon, South KoreaContact: SangHee Ha, MD, PhDTaking people
  • Inha University HospitalIncheon, South KoreaContact: Cindy W Yoon, MD, PhDTaking people
  • Jeju National University HospitalJeju City, South KoreaContact: Joong Goo Kim, MD, PhDTaking people
  • jeonbuk National University HospitalJeonju, South KoreaContact: Hyun Goo Kang, MD, PhDTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Bum Joon Kim, MD, PhDTaking people
  • Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Tae-Jin Song, MD, PhDTaking people
  • Hanyang University Seoul HospitalSeoul, South KoreaContact: Youngseo Kim, MD, PhDTaking people
  • Korea University Guro HospitalSeoul, South KoreaContact: Chi Kyung Kim, MD, PhDTaking people
  • Kyung Hee University HospitalSeoul, South KoreaContact: Hogeol Woo, MD, PhDTaking people
  • Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Kyung Chul Noh, MD, PhDTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Woo Keun Seo, MD, PhDTaking people
  • The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Minhwan Lee, MD, PhDTaking people
  • Yonsei University Health System - Gangnam Severance HospitalSeoul, South KoreaContact: Yo Han Jung, MD, PhDNot yet recruiting
  • Pusan National University Yangsan HospitalYangsan, South KoreaContact: Sungho Ahn, MD, PhDTaking people

About the trial

What the trial wants to find out

Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.

The 2 groups in the trial

  • CA groupTreatment being tested

    Aspirin 100mg qd (21days), clopidogrel 75mg qd (180days), Cilostazol SR 100mg x 2cap (180days). In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.

    Treatment: Aspirin, Clopidogrel, and Cilostazol

  • PA groupPlacebo, for comparison

    Aspirin 100mg (21days), clopidogrel 75mg qd (180days), Placebo x 2cap (180days). In case of stenting, aspirin will be added to placebo and clopidogrel until 90 days after stenting.

    Treatment: Aspirin, Clopidogrel, and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial
Plain-language title
Testing an added blood-thinning drug after a stroke from narrowed large arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 March 2026